Why the study?
Do DPP-4 inhibitors reduce all-cause mortality and MACEs compared with sulfonylureas when added to metformin therapy in patients with type 2 diabetes mellitus?
Population
20,178 patients with type 2 diabetes mellitus aged 20 years or older in Taiwan
Comparison
Dipeptidyl peptidase-4 inhibitors added to… vs Sulfonylureas added to metformin therapy
Design
Cohort
Follow-up
until death or 31 December 2013
Authors
Loading...
DPP-4 inhibitors were associated with lower risks than sulfonylureas; leaves open whether findings reflect benefit or residual confounding.
Do DPP-4 inhibitors reduce all-cause mortality and MACEs compared with sulfonylureas when added to metformin therapy in patients with type 2 diabetes mellitus?
Adding DPP-4 inhibitors to metformin in patients with T2DM is associated with reduced all-cause mortality, MACE, and hypoglycemia compared to adding sulfonylureas.
Ou et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: